Skip to content

Inspirata Approved Partner

Dynamyx™ from Inspirata affords an ‘open’ architecture purposely designed to enable healthcare providers to arrive at their preferred blend of laboratory and diagnostic technologies. Inspirata’s technical partnership with DeepMed IO ensures the seamless integration of its DeepPath™ AI-based automated lymph node metastasis detection solution into Dynamyx™.

DEM_Color

DeepMed IO is a UK-based high technology company focused on creating AI-powered solutions for digital pathology. Working together with expert pathologists, world class biobanks and leading research and healthcare institutions, DeepMed maintains the practitioners at the center of its product design process, striving to deliver efficiency together with high sensitivity and unparalleled accuracy. DeepMed has a pipeline of AI-powered products with the purpose of supporting pathologists in accelerating their workflows in several feature detection and tumor grading applications. The aim is to accelerate histopathology processes, maintain or increase accuracy, save costs and free valuable time for value-added tasks.

Questions about the Inspirata and DeepMed IO partnership?

INSPIRATA AND DEEPMED IO

Inspirata Dynamyx™ and DeepMed IO DeepPath™ customers can now avail AI-powered pre-annotation of macro- and micro-metastasis regions, as well as isolated tumor cells (ITCs) found on multiple-cancer lymph node sections, directly within the histopathology workflow.

The DeepMed IO proprietary-trained neural networks scan each qualifying lymph node image just after digitization and output an annotation layer with all regions of interest highlighted for inspection by the clinician.

  • Single-button navigation between regions of interest for rapid inspection and decision making.
  • Automatic measurements of features for accelerated reporting – positive slides are resolved in seconds.
  • Algorithms are biased towards sensitivity – low false negatives rates.
  • The system can arrange slides from single patient cases to present positives first, saving substantial time. Patient triaging can be programmed based on lab-specific rules.

The DeepPath™ annotation layer and regions of interest navigation buttons are seamlessly integrated within the main workflow of Dynamyx™ to ensure fast adoption and with only a modest learning curve.

ABOUT DEEPPATH™ FROM DEEPMED IO

The DeepPath™ solution is using the power of state-of-the-art machine learning technology, trained by a proprietary and extensive knowledge base, curated by expert pathologists. The software is capable of examining the digitised images in minute detail and identifying and quantifying regions of interest. Great care has been taken to integrate the solution with the routine Dynamyx™ workflow so as to require minimal training. AI annotation can be toggled on or off by the user to help accelerate the examination of the slide or as a quality control measure. Decision power remains firmly with the expert pathologist, ensuring the optimal partnership between human and machine.

DeepMed IO is extremely excited to have the opportunity to bring its solutions to expert pathologists through the Dynamyx ecosystem. Inspirata’s open platform approach and amazing collegial spirit help foster innovation and deliver efficiency and accuracy to our customers’ workflows.

– Konstantinos Vougas
Managing Director
DeepMed IO

PARTNER RESOURCES

Dynamyx is CE-marked per Annex III of Directive 98/79/EC on in vitro diagnostic medical devices.

In the USA, Dynamyx is for research use only (RUO) and not for use in diagnostic procedures.

DeepMed IO DeepPath™ is  for research use only and not for use in diagnostic procedures.

Questions about the Inspirata and DeepMed IO partnership?

Inspirata Approved Partners